SDN-1001

SDN-1001 is a preclinical **glycoconjugate immunostimulator** being developed by **Sidanis Pharma** as a **host defense modifier** for bacterial and fungal infections, including respiratory tract infections. Rather than directly killing pathogens like a conventional antibiotic, the agent is described as selectively stimulating innate immune defenses so immune cells can recognize and eliminate a broad range of microorganisms more effectively, including Gram-positive and Gram-negative bacteria and fungi. It has been administered by injection in animal studies, where a single dose reportedly conferred short-term protection against lethal pathogen challenge in mice, and in a pilot study in farm animals a single injection reportedly mitigated severe respiratory tract infection without notable local or systemic intolerance. Development appears focused on both human and veterinary applications, particularly settings involving infection susceptibility or impaired host defense.

Other names

glycoconjugate immunostimulatorhost defense modifierimmunostimulator